Shigella vaccine - AVANT

Drug Profile

Shigella vaccine - AVANT

Latest Information Update: 18 Jul 2008

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics
  • Developer Celldex Therapeutics Inc
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Shigella infections

Most Recent Events

  • 18 Jul 2008 Preclinical development is ongoing
  • 01 Aug 2006 This compound is still in active development
  • 15 Jul 2004 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top